See the DrugPatentWatch profile for Risperdal
Risperidone Patent Expiration
The patent for Risperdal, with the active ingredient risperidone, has expired [1]. This means that generic versions of the drug are available [1].
When Did Risperdal Patents Expire?
The primary patent for Risperdal, held by Janssen Pharmaceutica, expired in 2003 [1]. However, there were subsequent patents and exclusivities that could have extended market protection for the brand-name drug.
Generic Risperidone Availability
With the expiration of its core patents, generic risperidone became available to consumers. The availability of generics generally leads to lower medication costs [1].
Why Are Patents Important for Drugs?
Drug patents grant exclusive rights to the inventor for a specific period, allowing them to recoup research and development costs. Once a patent expires, other companies can produce and sell generic versions of the drug, increasing competition and often lowering prices [1].
Risperdal vs. Generic Risperidone
Generic risperidone is chemically identical to brand-name Risperdal. This means it contains the same active ingredient in the same dosage form and strength, and it is absorbed into the body in the same way. Regulatory agencies like the U.S. Food and Drug Administration (FDA) require generic drugs to be bioequivalent to their brand-name counterparts [1].
Legal Challenges and Patent Extensions
Pharmaceutical companies sometimes pursue legal strategies to extend patent protection for their drugs beyond the initial expiration date. This can involve obtaining new patents for different formulations, delivery methods, or manufacturing processes, or engaging in litigation to defend their intellectual property [1].
Sources:
1. https://drugpatentwatch.com/